At what enterprise value was VETPARTNERS acquired in 2023?

During the acquisition of VETPARTNERS by EQT PARTNERS in 2023, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b AUD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VETPARTNERS when it was acquired by EQT PARTNERS?

The estimated EV/EBITDA multiple for VETPARTNERS is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was VETPARTNERS acquired by EQT PARTNERS?

VETPARTNERS was acquired by EQT PARTNERS in 2023.

What was the revenue of VETPARTNERS at the time of the deal?

The revenue of VETPARTNERS at the time of the deal is estimated to be in the range of 450M - 900M AUD. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of VETPARTNERS during the acquisition?

VETPARTNERS's EBITDA is estimated to be in the range of 100M - 200M AUD. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VETPARTNERS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VETPARTNERS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://eqtgroup.com/news/eqt-to-acquire-vetpartners-the-leading-provider-of-veterinary-and-animal-health-services-in-australia-and-new-zealand-2023-10-11

← DATABASE

Home Database Healthcare & PharmaVETPARTNERS

10/2023

VETPARTNERS acquired by EQT PARTNERS

AUSTRALIA Health Providers / Outpatient Care / Vet Clinics EV 1b - 4b AUD

Context

EQT, through its BPEA Fund VIII, agreed to acquire VetPartners from National Veterinary Associates (NVA), a portfolio company of JAB Holding. The transaction represents a major entry for EQT into the ANZ veterinary services market, following its extensive track record with IVC Evidensia in Europe. The strategic objective is to consolidate VetPartners' leadership position through significant capital investment in digital tools, advanced diagnostic equipment, and recruitment initiatives. The deal was finalized through a fast-tracked auction process where EQT was selected as the preferred bidder over rival private equity firms. Under EQT's ownership, the group will continue its aggressive expansion across the fragmented Australasian market while enhancing its specialized veterinary training centers and managed services division (United Vets Group).

VETPARTNERS, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2016, VetPartners is the leading veterinary service provider in Australia and New Zealand, with a growing presence in Singapore. The group operates a network of approximately 267 community-based general practice clinics and specialty hospitals. It employs over 1,300 veterinarians and 3,000 nurses, facilitating more than 3.2 million pet visits annually. The company utilizes a "Join Us, Stay You" decentralized model that allows local clinics to maintain their brand identity and clinical autonomy while benefiting from centralized business support and high-tech infrastructure.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (AUD)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
12/2023	ESSLING CAPITAL	X-RAY PHOCEA	FRANCE	Health Providers	X-Ray Phocea, a leading medical imaging group in Southern France, has secured a strategic minority investment from Essling Expansion, alongside Bpifrance and SOFIPACA. Despite this new capital entry, the majority of the group�s shareholding remains in the hands of its 20 associate radiologists, preserving a practitioner-led management model
12/2023	ANDERA PARTNERS	GROUPE IMAGERIE CARDINET	FRANCE	Health Providers	Andera Acto is providing minority financing to Imagerie Cardinet to support its next phase of expansion. The transaction is structured to allow the associate radiologists to maintain a massive majority, representing approximately 95% of the capital
08/2023	QUADRIVIO GROUP	THE PRIVATE CLINIC (TPC)	UNITED KINGDOM	Health Providers	Quadrivio Group has acquired a majority stake in The Private Clinic from BlueGem Capital Partners to serve as a platform for its "Silver Economy" strategy. The industrial logic is anchored in the "healthy longevity" megatrend: as the population ages, demand for aesthetic and wellness treatments among the affluent over-50s is booming
08/2023	BAIN CAPITAL	ESTIA HEALTH	AUSTRALIA	Health Providers	Following a five-month bidding process, Bain Capital has entered into a definitive Scheme Implementation Agreement to acquire 100% of the share capital of Australian aged care operator Estia Health Limited
07/2023	MEDIAN KLINIKEN	HESTIA ALLIANCE	SPAIN	Health Providers	MEDIAN Group, backed by Waterland Private Equity, acquired Hestia Alliance, one of Spain's largest private post-acute and mental health care providers, marking MEDIAN's first entry into the Spanish healthcare market
06/2023	ARDIAN	MON VETO	FRANCE	Health Providers	Ardian acquired a minority stake (approximately 20%) in Mon Veto through a primary capital increase. This "pure cash-in" operation was designed to strengthen the group's equity base without any cash-out for the founding veterinarians
06/2023	PARQUEST CAPITAL	IMANEO	FRANCE	Health Providers	Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector
11/2022	RADNET	HEART & LUNG IMAGING	UNITED KINGDOM	Health Providers	RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases
10/2022	CBPE CAPITAL	VEINCENTRE	UNITED KINGDOM	Health Providers	CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics
09/2022	ORADIANSE	REVEL	FRANCE	Health Providers	Oradianse, a leading group of radiologists, has acquired a radiology practice in Revel, located in the Haute-Garonne region near Toulouse. This move is part of the company's territorial development strategy, aimed at strengthening its presence in the Occitanie region and consolidating its national network of medical imaging centers

REFERENCES

Valuation range: EV 1b - 4b AUD

Revenue range: 450M - 900M AUD

EBITDA range: 100M - 200M AUD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VETPARTNERS by EQT PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: eqt partners